RCUS 241115 22.50C (RCUS241115C22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

RCUS241115C22500

Watchlist

1.35
0.000.00%

15min DelayTrading Oct 21 09:30 ET

1.40High1.35Low

Intraday

5D
Daily

News

Unveiling 5 Analyst Insights On Arcus Biosciences
BenzingaOct 21 10:00 ET
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Moomoo NewsOct 21 07:34 ET · Ratings
Arcus Biosciences Analyst Ratings
BenzingaOct 21 06:46 ET · Ratings
H.C. Wainwright Initiates Arcus Biosciences(RCUS.US) With Hold Rating, Announces Target Price $20
Moomoo NewsOct 21 06:31 ET · Ratings
Arcus Biosciences Initiated With a Neutral at H.C. Wainwright
TipRanksOct 21 06:17 ET · Ratings
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $25
Moomoo NewsOct 17 04:33 ET · Ratings

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Moomoo AI

Mar 22 05:31

The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.

Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding

Moomoo AI

Feb 23 04:42

Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.

Optimistic Investors Push Arcus Biosciences, Inc. (NYSE:RCUS) Shares Up 27% But Growth Is Lacking

Moomoo AI

Feb 13 04:49

Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation